Can St. Jude Medical Inc. Win This Crucial Market?

The transcatheter aortic valve replacement market has attracted a lot of attention around the device industry, and St. Jude's not wasting time looking for its share of the opportunity.

May 15, 2014 at 6:30PM

Cardiac device giant St. Jude Medical (NYSE:STJ) hasn't exactly posted a repeat performance of its star-studded 2013 this year.

Despite gaining more than 35% over the past year, St. Jude's stock has dropped off by more than 3% over the past three months. The company's lackluster performance hasn't inspired investors, either, as total cardiovascular sales fell 1% in its most recent quarter, with its largest business, cardiac rhythm management, barely managing growth. Add to that St. Jude's struggles to keep up with the leaders in the exciting transcatheter aortic valve replacement market, and it's been a downbeat year so far for this medical device staple.

But St. Jude may be ready to turn the corner on that last issue. A breakthrough with the company's Portico heart valve has the company thinking big in the prized U.S. market, but should investors expect St. Jude to close the gap between it and the market's early leaders, Edwards Lifesciences (NYSE:EW) and Medtronic (NYSE:MDT)?

St. Jude's best growth hope?
St. Jude's Portico heart valve has experienced some early success in its young life: European regulators first approved the device back in 2012 and added a second approval for a different size of the Portico last year. But the big market in this heart valve battle is the U.S. Edwards Lifesciences, the early leader in the market, received FDA approval in 2011. Medtronic's burst onto the scene to compete with Edwards in a hard-fought battle recently after the company's CoreValve device received U.S. approval this January.

While the Portico hasn't gotten that far yet, it did strike a major success recently. St. Jude announced on Tuesday that doctors conducted the first two American implants of the Portico in patients. That's not the end goal for St. Jude by far, but it's a big step toward eventual potential U.S. approval, along with ongoing randomized trials of the devices around the country.

St Jude Portico Tavr

St. Jude's Portico TAVR device. Source: St. Jude Media Gallery

While Edwards Lifesciences and Medtronic have dug into this market already, St. Jude's not backing out of the fight -- and for good reason. St. Jude's Portico offers the advantage of being movable where it's implanted in the heart, a feature that's thought to reduce possible risk for patients.

Of course, for investors, the real advantage is in this market's potential.

Edwards and Medtronic have waged a protracted battle across the U.S. and Europe for leadership in this market, which the Millennium Research Group projected back in 2012 would provide almost all of the growth of the overall American heart valve market to $1.5 billion by 2016. For a cardiac device market that's struggled to gain ground and revenue in light of tight competition and falling prices, this kind of a growth opportunity is a can't-miss situation for investors and firms alike. Other firms have taken notice: Boston Scientific has pushed into the area with its own Lotus heart valve as of late. While Boston's far off from possible U.S. approval like St. Jude, it scored European regulatory approval for the Lotus last October.

St. Jude needs all the help it can get. The company's made significant strides in its promising atrial fibrillation business, which saw revenues gain 10% in constant currency year over year in the firm's most recent quarter. But that business is tiny in terms of sales compared to St. Jude's dominant CRM and cardiovascular groups, which rely on devices such as implantable cardioverter defibrillators and pacemakers -- products that have been anything but growth-friendly lately. Restocking the product portfolio with devices such as the Portico and in niches such as atrial fibrillation is pivotal for St. Jude's long-term growth plans.

Keeping an eye on the long term
In all, the company still has a long way to go with the Portico. While the first two U.S. implantations of the Portico is a big step for St. Jude, it's just one accomplishment in the journey toward American regulatory approval -- and toward catching up with Edwards and Medtronic in this hot industry. Yet even though St. Jude's behind in the race, this is one battle that investors can't afford to take their eyes off of. St. Jude's in big need for growth, and the Portico (and the transcatheter aortic valve replacement market) looks like it could be a great option for helping to alleviate that problem in the long term.

Don't miss out on the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information

Compare Brokers